Business
Appointment of Finance Director
Appointment of Finance Director.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8031A Allergy Therapeutics PLC 10 June 2016 \n\n \n \n \n \n \n10 June 2016\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nAppointment of Finance Director\n \nAllergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Nick Wykeman to the Board as Finance Director with immediate effect.\nMr Wykeman was most recently at Skyepharma PLC until August 2015 where he was the Group Financial Controller for six years. Prior to that, Mr Wykeman had also worked at Quest International (a part of ICI PLC) as the Group Financial Controller (Special Projects), following six years at Deloitte & Touche. Mr Wykeman has a BSc (Hons) in Economics and is a qualified accountant, being a member of the Institute of Chartered Accountants of England and Wales.\nMr Wykeman replaces Ian Postlethwaite, who, further to the announcement made on 17 March 2016, has now resigned from the Company and the Board with immediate effect.\nPeter Jensen, Chairman of Allergy Therapeutics, said: \"We welcome Nick to his role as Finance Director and look forward to his contribution to the Company as we continue to grow the business internationally on all fronts. His international experience in life sciences is well suited to the role and we're pleased to have attracted him to Allergy Therapeutics.\n\"We also thank Ian Postlethwaite for his fourteen, successful years with Allergy Therapeutics and wish him well for his future.\"\nNicolas Alexander Ulrich Wykeman, age 51, is currently a director of the following company:\nCurrent Directorships\nWykeman Consulting BV\nAllergy Therapeutics confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies.\n \nENDS\nFor further information please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Duncan Monteith, Corporate Finance\nTom Salvesen, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton\nallergytherapeutics@consilium-co...